GUJTHEM vs NOVARTIND: Stock Comparison
Gujarat Themis Biosyn Limited is the larger company by market capitalisation. Gujarat Themis Biosyn Limited shows a higher ROE, faster revenue growth and a higher ROCE, while Novartis India Limited shows a lower P/E, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GUJTHEM leads 8; NOVARTIND leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GUJTHEM | NOVARTIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GUJTHEM | NOVARTIND |
|---|---|---|
| Live Price | ₹404.7 | ₹1,486.3 |
| Day Change | -1.7% | -1.06% |
| Volume | 9.27 L | 6,845 |
| 52-Week High | ₹479 | ₹1,780 |
| 52-Week Low | ₹225.05 | ₹950 |
| Distance from 52W High | -15.51% | -16.5% |
Valuation
| Metric | GUJTHEM | NOVARTIND |
|---|---|---|
| Market Cap | ₹4,377 Cr | ₹3,664 Cr |
| P/E Ratio | 91.57x | 37.65x |
| P/B Ratio | 15.5x | 4.5x |
| EPS | ₹4.26 | ₹37.76 |
| Book Value | ₹26.41 | ₹331.34 |
| Dividend Yield | 0.19% | 1.7% |
Growth
| Metric | GUJTHEM | NOVARTIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 17.2% | 8% |
| EPS Growth (TTM YoY) | -9.1% | -13.8% |
| Qtr Sales Growth | 17.2% | 7.95% |
| Qtr Profit Growth | -9.25% | -13.8% |
Profitability & Leverage
| Metric | GUJTHEM | NOVARTIND |
|---|---|---|
| ROE | 17.4% | 11.6% |
| ROCE | 17.9% | 16.2% |
| Net Margin | 28.15% | 26.3% |
| Operating Margin | 45.6% | 26.6% |
| Debt to Equity | 0.56x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GUJTHEM | NOVARTIND |
|---|---|---|
| Promoter Holding | 70.86% | 0% |
| FII Holding | 1.77%▼ 0.03 pp | 0.16%▼ 0.01 pp |
| DII Holding | 1.18% | 1.36%▲ 0.83 pp |
| Public Holding | 26.19%▲ 0.03 pp | 27.8%▼ 0.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Gujarat Themis Biosyn Limited and Novartis India Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.